<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686916</url>
  </required_header>
  <id_info>
    <org_study_id>IP2018CS01</org_study_id>
    <nct_id>NCT04686916</nct_id>
  </id_info>
  <brief_title>Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Crossover Trial Studying the Efficacy and Safety of IP2018 in Young, Depressed, Erectile Dysfunction (ED) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Initiator Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Initiator Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IIa, randomised, double-blind, placebo-controlled, 3-period, crossover study&#xD;
      to assess two single oral dose levels of IP2018. It is planned to enrol 24 patients. Patients&#xD;
      will take part in three treatment periods, in which they will be randomised to receive either&#xD;
      a single dose of IP2018 or a single dose of placebo in each treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile Function</measure>
    <time_frame>A 6 hours time interval after dosing</time_frame>
    <description>Rigiscan device assessment of tumescence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment</measure>
    <time_frame>From randomisation to end of study participation</time_frame>
    <description>Clinical safety data from AE reporting, 12-lead electrocardiograms (ECGs), vital signs (standing and supine blood pressure, heart rate and oral temperature [supine only]), physical examinations and clinical laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of IP2018</measure>
    <time_frame>From start to end of assessments</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of IP2018</measure>
    <time_frame>From start to end of assessment</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>IP2018_dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP2018_dose1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IP2018_dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP2018_dose2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IP2018</intervention_name>
    <description>Test drug</description>
    <arm_group_label>IP2018_dose 1</arm_group_label>
    <arm_group_label>IP2018_dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Male patients with a diagnosis of mild to moderate depression and ED as determined from&#xD;
        the Hamilton depression scale score of 7 to 23 and International Index of Erectile Function&#xD;
        (IIEF-5) score of 12 to 18, respectively, with a body mass index of 18 to 32 kg/m2&#xD;
        (inclusive), of any ethnic origin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal (GI),&#xD;
        haematological, endocrinological, metabolic, neurological, psychiatric conditions, or&#xD;
        history of fainting or syncope or such condition that, in the opinion of Investigator, may&#xD;
        place the patient at unacceptable risk as a participant in the study, may interfere with&#xD;
        the interpretation of safety or tolerability data obtained in this study, or may interfere&#xD;
        with the absorption, distribution, metabolism or excretion of drugs, or with the completion&#xD;
        of treatment according to this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patients with a diagnosis of mild to moderate depression and erectile dysfunction</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Greenhalgh, BSc, MBChB, MRCGP</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAC UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claus Olesen, PhD</last_name>
    <phone>61260035</phone>
    <email>ceo@initiatorpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikael Thomsen, PhD</last_name>
    <phone>23276134</phone>
    <email>mt@initiatorpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MAC</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

